04-20-2005, 07:08 PM
|
 |
Registered User
|
|
Join Date: Mar 2005
Posts: 199
Thanks: 0
Thanked 5 Times in 5 Posts
|
|
|
Hydroxyurea in thalassemia intermedia-a promising therapy
Source:
Ann Hematol. 2005 Apr 19; [Epub ahead of print]
Hydroxyurea in thalassemia intermedia-a promising therapy.
Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.
Department of Haematology, All India Institute of Medical Sciences, New Delhi, India, vedpchoudhry@yahoo.co.in.
Pharmacological agents such as hydroxyurea (HU) have been known to cause induction of fetal hemoglobin and possibly may alleviate the symptoms in thalassemia intermedia patients. Thirty-seven patients with beta-thalassemia intermedia were enrolled to assess response to HU therapy. Major response was defined as transfusion independence or hemoglobin rise of more than 20 g/l and minor response as rise in hemoglobin of 10-20 g/l or reduction in transfusion frequency by 50%. The median age was 10 years (range: 4-50 years) and median follow-up was 12 months (range: 4-36 months). Twenty-six patients (70.2%) showed response to HU therapy. Seventeen patients (45.9%) were major responders, and nine patients (24.3%) showed minor response. There was no correlation of response with beta-thalassemia mutation or XmnI polymorphism; however, the presence of alpha(3.7) deletion was associated with major response in three patients. Mean fetal hemoglobin (HbF) levels rose on HU therapy. Older age, low baseline F cell percent, and low baseline HbF levels (below 10%) were predictors of poor response. Response was evident within 1 month of starting HU therapy in the majority of responders. Thus, a short trial of HU therapy can predict durable response.
PMID: 15838670 [PubMed - as supplied by publisher]
|
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
